A Phase 3 Study of Solosec® for the Treatment of Trichomoniasis
Multi-center, Prospective, Randomized, Placebo-Controlled, Delayed Treatment, Double-Blind Study to Evaluate the Effectiveness and Safety of a Single Oral Dose of Solosec® for the Treatment of Trichomoniasis
Sponsor: Lupin Research Inc
This PHASE3 trial investigates Trichomonas Infection and is currently completed. Lupin Research Inc leads this study, which shows 8 recorded versions since 2019 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Nov 2023 — Jul 2024 [monthly]
Completed PHASE3
-
Oct 2021 — Nov 2023 [monthly]
Completed PHASE3
-
Jan 2021 — Oct 2021 [monthly]
Completed PHASE3
▶ Show 3 earlier versions
-
May 2020 — Jan 2021 [monthly]
Completed PHASE3
Status: Recruiting → Completed
-
Sep 2019 — May 2020 [monthly]
Recruiting PHASE3
-
Jun 2019 — Sep 2019 [monthly]
Recruiting PHASE3
First recorded
Apr 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Lupin Research Inc
For direct contact, visit the study record on ClinicalTrials.gov .